IMPACT Therapeutics Inc. Annou...
IMPACT Therapeutics successful...
IMPACT poster 2013- AACR
IMPACT poster 2011- AACR
IMS reported Impact Therapeuti...
  Founded in 2009 and based in Nanjing, China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and best-in-class therapeutics to treat cancer and other life-threatening diseases. Since its inception IMPACT has successfully built a new and effective scientific and business model and made tremendous progress in ...
Microtubule Inhibitors
Description: IMPACT has discovered two series of novel small molecular potent microtubule inhibitors. In comparison with...
PARP inhibitors
Description: IMPACT has discovered two series of novel PARP inhibitors with more than 60 novel compounds that are many ...
Hedgehog Pathway Inhibit...
Description: IMPACT has discovered three series of novel Hedgehog pathway inhibitors, and has identified more than 10 co...
  • CEO&CSO
  • SVP&CTO
Dr. Ye Edward Tian, the CEO and CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow and Associate Director, Dr. Tian played critical roles in several drug discovery projects that
Dr. Sui Xiong Cai, the SVP and CTO, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and
Home About Us Science and Business Model News Center Virtual Tour Therapeutics Areas Careers Contact Us  
  IMPACT Therapeutics copyright 2011    http://www.impacttherapeutics.com    
All rights reserved.     苏ICP备10223379号